1 Min Read
May 15 (Reuters) - Eiger Biopharmaceuticals Inc:
* Eiger Biopharmaceuticals Inc says completes enrollment of phase 2 liberty study of ubenimex in pulmonary arterial hypertension Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.